Posted by Michael Wonder on 21 Jan 2020
European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma
21 January 2020 - Novel combination regimen includes first-in-class antibody-drug conjugate that specifically targets CD79b.
Roche today announced that the European Commission has granted conditional marketing authorisation for Polivy (polatuzumab vedotin), in combination with bendamustine plus MabThera (rituximab) (BR), for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not candidates for a haematopoietic stem cell transplant.
The conditional approval is based on the results from the phase Ib/II GO29365 study, the first and only clinical trial to show higher response rates and improved overall survival (OS) compared to BR, a commonly used regimen, in people with R/R DLBCL who are not candidates for a haematopoietic stem cell transplant.
